

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**KUANGCHI SCIENCE LIMITED**

**光啟科學有限公司**

*(Incorporated in Bermuda with limited liability)*

**(Stock code: 439)**

- (i) RE-DESIGNATION OF DIRECTOR;**  
**(ii) CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTORS;**  
**(iii) CHANGE IN COMPOSITION OF BOARD COMMITTEES;**  
**AND**  
**(iv) COMPLIANCE WITH RULE 13.92 OF THE LISTING RULES**

**RE-DESIGNATION OF DIRECTOR**

The board of directors (“**Board**”) of KuangChi Science Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that Dr. Wong Kai Kit (黃繼傑博士) (“**Dr. Wong**”), an independent non-executive Director of the Company, has been re-designated as a non-executive Director of the Company with effect from 9 December 2025.

The biographical details of Dr. Wong are as follows:

Dr. Wong, aged 52, joined the Company in August 2014. He was an independent non-executive Director of the Company. Dr. Wong was appointed a professor at the Department of Electronic and Electrical Engineering, University College London, United Kingdom in October 2015. Dr. Wong had other teaching and research roles in universities and education institutes in Hong Kong, the United States of America and the United Kingdom. Dr. Wong is an academician of The Institution of Engineering and Technology Inc. and a senior fellow of The Institute of Electrical and Electronics Engineers Inc.. Dr. Wong obtained a doctoral degree, a master's degree and a bachelor's degree from the Hong Kong University of Science and Technology in 2001, 1998 and 1996 respectively.

Save as disclosed above, Dr. Wong has not previously held and currently does not hold any position with the Company and its subsidiaries. He has not held other directorships in the last three years preceding the date of this announcement in public companies the securities of which are listed on any securities market in Hong Kong or overseas, and does not have any relationship with any other directors, senior management or substantial or controlling shareholders of the Company.

As at the date of this announcement, Dr. Wong does not have any interest in any shares or underlying shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance.

By an appointment letter entered into with the Company on 9 December 2025, Dr. Wong will serve as a non-executive Director for a term of three years commencing from 9 December 2025 and unless terminated by not less than 3 months' notice in writing served by either party to the other. Dr. Wong is subject to retirement and re-election at the next following annual general meeting of the Company after his appointment and thereafter subject to retirement by rotation and re-election at least once in every three years in accordance with the bye-laws of the Company. According to the appointment letter, Dr. Wong is entitled to a director's fee of HK\$250,000 per annum, which is determined by the Board based on the recommendation of the remuneration committee ("**Remuneration Committee**") of the Company with reference to his qualification, experience and prevailing market rate and the remuneration policy of the Company. The fee will be subject to review by the Remuneration Committee and the Board from time to time.

Save as disclosed above, the Board is not aware of any other matters that need to be brought to the attention of the shareholders or the Stock Exchange and there is no information that is required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on the Stock Exchange (“**Listing Rules**”) in relation to Dr. Wong’s appointment.

## **CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTORS**

The Board of the Company hereby announces that Dr. Wu Zhili (“**Dr. Wu**”) has resigned as an independent non-executive Director, and as a member of each of the audit committee (“**Audit Committee**”), the Remuneration Committee, and the nomination committee (“**Nomination Committee**”) of the Company with effect from 9 December 2025, due to his wish to devote more time to pursue his other business commitments. Dr. Wu has confirmed that he has no disagreement with the Board and there is no matter that needs to be brought to the attention of the shareholders of the Company in connection with his resignation.

The Board is also pleased to announce that with effect from 9 December 2025, Ms. Chiu Wing Yan (招穎欣女士) (“**Ms. Chiu**”) and Mr. Zhang Xinxing (張新星先生) (“**Mr. Zhang**”) have been appointed as an independent non-executive Directors of the Company.

The biographic details of Ms. Chiu and Mr. Zhang are as follows:

### **Ms. Chiu Wing Yan (招穎欣女士)**

Ms. Chiu, aged 34, has over 10 years of experience in the fields of auditing, accounting and finance, internal control and corporate governance practices. Ms. Chiu serves as the Managing Director of a consulting company which specializes in providing financial reporting services and internal control reviews to listed companies, with a dedicated practice to virtual assets. Ms. Chiu graduated from the City University of Hong Kong with a bachelor degree of Business Administration (Honours) in Accountancy and she is a member of the Hong Kong Institute of Certified Public Accountants.

By an appointment letter entered into with the Company on 9 December 2025, Ms. Chiu will serve as an independent non-executive Director for a term of three years commencing from 9 December 2025 and unless terminated by not less than 3 months' notice in writing served by either party to the other. Ms. Chiu is subject to retirement and re-election at the next following annual general meeting of the Company after her appointment and thereafter subject to retirement by rotation and re-election at least once in every three years in accordance with the bye-laws of the Company. According to the appointment letter, Ms. Chiu is entitled to a director's fee of HK\$250,000 per annum, which is determined by the Board based on the recommendation of the Remuneration Committee of the Company with reference to her qualification, experience and prevailing market rate and the remuneration policy of the Company. The fee will be subject to review by the Remuneration Committee and the Board from time to time.

Ms. Chiu has confirmed that (i) she meets the independence criteria as set out in Rule 3.13 of the Listing Rules; (ii) she has no past or present financial or other interest in the business of the Company or its subsidiaries or any connection with any core connected person (as defined under the Listing Rules) of the Company; and (iii) there are no other factors that may affect her independence at the time of her appointment.

As at the date of this announcement, save as disclosed above, Ms. Chiu (i) does not hold any other position in the Company or other subsidiaries; (ii) did not hold directorship in other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (iii) does not have any relationship with any Directors, supervisors, senior management or substantial or controlling shareholders of the Company; and (iv) does not have any interest in the securities of the Company and its associated corporations within the meaning under Part XV of the SFO.

**Mr. Zhang Xinxing (張新星先生)**

Mr. Zhang, aged 39, has over 13 years of experience in legal practice, accumulating extensive professional expertise. Mr. Zhang is currently a Senior Partner at Hylands Law Firm, where he practices as a full-time attorney. He obtained a Master's degree in Jurisprudence from Heilongjiang University in June 2012 and was admitted to practice as a lawyer in China in the same year. Furthermore, Mr. Zhang holds several professional qualifications, including the Board Secretary Qualification Certificate (Shenzhen Stock Exchange), the Advanced Enterprise Compliance Officer Professional Competency Certificate, and the Fund and Securities Practicing Qualification Certificate.

By an appointment letter entered into with the Company on 9 December 2025, Mr. Zhang will serve as an independent non-executive Director for a term of three years commencing from 9 December 2025 and unless terminated by not less than 3 months' notice in writing served by either party to the other. Mr. Zhang is subject to retirement and re-election at the next following annual general meeting of the Company after his appointment and thereafter subject to retirement by rotation and re-election at least once in every three years in accordance with the bye-laws of the Company. According to the appointment letter, Mr. Zhang is entitled to a director's fee of HK\$250,000 per annum, which is determined by the Board based on the recommendation of the Remuneration Committee of the Company with reference to his qualification, experience and prevailing market rate and the remuneration policy of the Company. The fee will be subject to review by the Remuneration Committee and the Board from time to time.

Mr. Zhang has confirmed that (i) he meets the independence criteria as set out in Rule 3.13 of the Listing Rules; (ii) he has no past or present financial or other interest in the business of the Company or its subsidiaries or any connection with any core connected person (as defined under the Listing Rules) of the Company; and (iii) there are no other factors that may affect his independence at the time of his appointment.

As at the date of this announcement, save as disclosed above, Mr. Zhang (i) does not hold any other position in the Company or other subsidiaries; (ii) did not hold directorship in other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (iii) does not have any relationship with any Directors, supervisors, senior management or substantial or controlling shareholders of the Company; and (iv) does not have any interest in the securities of the Company and its associated corporations within the meaning under Part XV of the SFO.

## **CHANGE IN COMPOSITION OF BOARD COMMITTEES**

Following the appointment of Ms. Chiu and Mr. Zhang as independent non-executive Directors, the re-designation of Dr. Wong from independent non-executive Director to non-executive Director, and the resignation of Dr. Wu as an independent non-executive Director, the Board hereby announces the following changes to the Audit Committee, the Remuneration Committee and the Nomination Committee shall become effective on 9 December 2025:

- Ms. Chiu appointed as Chairman of the Remuneration Committee, a member of each of the Audit Committee and the Nomination Committee;
- Mr. Zhang appointed as a member of each of the Audit Committee, the Remuneration Committee and the Nomination Committee;
- Dr. Wong resigned as Chairman of the Remuneration Committee, a member of each of the Audit Committee and the Nomination Committee; and
- Dr. Wu resigned as member of each of the Audit Committee, the Remuneration Committee and the Nomination Committee.

## **COMPLIANCE WITH RULE 13.92 OF THE LISTING RULES**

Pursuant to Rule 13.92 of the Listing Rules, the Stock Exchange will not consider diversity to be achieved for a single gender board. Following the appointment of Ms. Chiu as an independent non-executive Director, the Company has complied with the requirement of diversity of board members under Rule 13.92 of the Listing Rules.

The Board would like to take this opportunity to express its gratitude to Dr. Wu for his valuable contributions to the Group during his tenure of service, and also express its warm welcome to Dr. Wong on his re-designation, Ms. Chiu and Mr. Zhang for joining the Company.

By Order of the Board  
**KuangChi Science Limited**  
**Cheng Chi Chung Kevin**  
*Company Secretary*

Hong Kong, 9 December 2025

*As at the date of this announcement, the Board comprises three executive Directors, namely Dr. Zhang Yangyang, Dr. Liu Weiwen and Mr. Lin Ge; two non-executive Directors namely Dr. Wong Kai Kit and Mr. Li Chiu Ho; and three independent non-executive Directors, namely Mr. Choi Wing Koon, Mr. Zhang Xinxing and Ms. Chiu Wing Yan.*